Allosteric inhibition of RAN decreases miR-126 biogenesis in endothelial cells and controls acute myeloid leukemia growth.

Although the inhibitory effects on normal CD34+ hematopoietic cells were modest and did not reach statistical significance, it is important to underscore that any degree of perturbation of normal hematopoiesis may have potential clinical implications and therefore it will require careful evaluation in future pharmacologic and toxicologic studies to translate RAN-inhibitors into the clinic.

also in 111,027 other papers